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Abstract: BC-11 is an easily synthesized simple thiouronium-substituted phenylboronic 
acid, which has been shown to be cytotoxic on triple negative MDA-MB231 breast cancer 
cells by inducing a perturbation of cell cycle when administered at a concentration equal to 
its ED50 at 72 h (117 μM). Exposure of cells to BC-11, either pre-absorbed with a soluble 
preparation of the N-terminal fragment of urokinase-plasminogen activator (uPa), or in  
co-treatment with two different EGFR inhibitors, indicated that: (i) BC-11 acts via binding 
to the N-terminus of the enzyme where uPa- and EGF receptor-recognizing sites are present, 
thereby abrogating the growth-sustaining effect resulting from receptor binding; and (ii) the 
co-presence of the EGFR inhibitor PD153035 potentiates BC-11’s cytotoxicity. Exposure 
of cells to a higher concentration of BC-11 corresponding to its ED75 at 72 h (250 μM) 
caused additional impairment of mitochondrial activity, the production of reactive oxygen 
species and promotion of apoptosis. Therefore, BC-11 treatment appears to show potential 
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for the development of this class of compounds in the prevention and/or therapy of 
“aggressive” breast carcinoma. 
Keywords: boronic acid; BC-11; plasminogen activator inhibitor; breast cancer; cytotoxicity; 
MDA-MB231 cells 
 
1. Introduction 
It is known that treatment of triple-negative breast cancer (TNBC) faces limited options due to the 
absence of expression of estrogen and progesterone receptors and human epidermal growth factor 
receptor 2 by neoplastic cells, which accounts for the dearth of targeted therapies, elevated tumor 
aggressiveness and poor patient prognosis [1]. To this end, a gamut of non-targeted treatment approaches 
have been investigated, including the use of anti-angiogenetic drugs, tyrosine kinase and PARP 
inhibitors. However, modest success has been achieved, also due to the marked heterogeneity of this 
neoplastic histotype [2]. Recently, attention has focused also on the critical role that may be played  
by the tumor microenvironment on TNBC invasive and metastatic aptitude and on the possibility of 
finding targets in the extracellular milieu which can be used to counteract TNBC progression (for 
example, see [3]). 
A great deal of experimental evidence have indicated that the over-expression of the extracellular 
serine protease urokinase-plasminogen activator (uPa) and its receptor uPAR actively contributes to 
the aggressive phenotype of a number of cancers, and anti-uPaR antagonistic antibodies have been 
proven successful in reducing TNBC growth in vivo [4]. Carbamimidothioic acid (4-boronophenyl)methyl 
ester hydrobromide (BC-11) is a thiouronium-substituted phenylboronic acid [5,6] originally synthesized 
as part of a chemical fragment library aimed at targeting thrombin and related serine protease enzymes 
and found to be a selective, single digit micromolar uPa inhibitor [7,8] (Figure 1). In this study, our 
goal was to comprehensively examine the effects of BC-11 on an “in vitro” model system of TNBC, 
i.e., MDA-MB231 cells, with respect to viability and proliferation via a MTT assay, flow cytometric 
evaluation of cell cycle distribution, apoptosis modulation, and mitochondrial metabolic state. 
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Figure 1. Thioronium salts in this study. 
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The results indicate that BC-11 may be included in the list of drug-like molecules capable of inducing 
cytotoxicity on TNBC cells “in vitro”. 
2. Results and Discussion 
In a first set of assays, we checked the effect of dose- and time-dependent incubation with BC-11 on 
MDA-MB231 cell survival via an MTT assay. As shown in Figure 2A, when cells were exposed for 72 h 
to BC-11, viability decreased in a concentration-dependent manner with a half maximal effective dose 
(ED50) = 117 μM (BC-11 can be considered to be a “rule of three” fragment, with expected relatively 
moderate activity [9]). Doxorubicin, a clinically-employed anti-TNBC chemotherapeutic used as a 
control in the MTT assay, also decreased cell viability in a concentration-dependent manner with around 
a 32% lower ED50 (80 μM) under the present experimental conditions (Figure 2B). Interestingly, when 
cells were exposed to (benzylsulfanyl)methanimidamide hydrobromide (1) [5], a BC-11 analogue lacking 
the essential boron functionality that leads to serine protease inactivation [10,11] (Figure 1), no effect 
on viability could be observed (Figure 2C) thereby confirming the implication of the enzyme-linking 
moiety in BC-11’s inhibitory role. 
 
Figure 2. Effect of the different compounds on the viability of MDA-MB231 cells and of 
the exposure to BC-11 at its ED50 at 72 h on cell cycle. Dose-response curve for MDA-MB231 
cell viability after treatment with (A) BC-11; (B) doxorubicin and (C) 1 for 72 h. The ED50 
of BC-11 and doxorubicin are 117 and 80 μM, respectively. The ED75 of BC-11 is 250 μM. 
Error bars correspond to s.e.m. of three independent measurements; (D) DNA profiles of 
MDA-MB231 cells after 72 h of culture in control conditions (lighter in the background) 
and in the presence of 117 μM BC-11 (darker superimposed). Total cell distribution is 
reported in the annexed table. 
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The ED50 concentration of BC-11 was chosen for the first group of experiments aimed to glean 
more detailed data on the molecular mechanism of BC-11-induced toxicity on MDA-MB231 cells via 
flow cytometry. No significant death induction was observed after 24 and 48 h of incubation (not 
shown). The results obtained indicated that no apoptosis induction at early (6 and 24 h) and late stages 
(72 h) as well as reactive oxygen species (ROS) production or mitochondrial transmembrane potential 
(MMP) dissipation at 72 h of exposure to BC-11 could be observed (not shown). Interestingly, when 
MDA-MB231 cells were tested for the distribution of cell cycle phases, as shown in Figure 2D,  
72 h-exposure to BC-11 was linked with a decrease of the G0/G1 phase fraction (28.50% vs. 45.09%) 
and an increase of the S phase fraction (22.90% vs. 10.13%), indicative of a restrained progression 
through S phase conceivably due to the activation of the correspondent checkpoint. 
It is known that the amino-terminal fragment (ATF; aminoacids 1–135) of the non-catalytic A chain 
of uPa contains an “EGF-like” and a “kringle” domain, the first one encompassing the uPa receptor 
(uPaR) binding site and able to exert growth factor-like effects, and the second one intervening in the 
stabilization of ligand-receptor binding [10,11]. The ability of the uPa-uPaR system to sustain growth 
and abrogate apoptosis of normal and neoplastic cells, including MDA-MB231, via modulation of 
signal transducers (such as PI3K/Akt and Ras/ERK) has been widely acknowledged (e.g., [12,13]).  
In addition, interaction of uPa with the EGF receptor (EGFR) has also been reported (e.g., [14–16]), 
and, due to the EGFR positivity of TNBC [17], it has been acknowledged that this breast cancer 
subtype might benefit from EGFR-targeted therapy (e.g., [18]). In light of the literature precedents, we 
therefore ascertained whether BC-11’s cytotoxic activity on MDA-MB231 cells, could be ascribed to 
its binding to the uPaR- and EGFR-recognizing site of the enzyme, thereby competing with the 
receptor(s) and switching-off the related proliferation and survival-promoting intracellular signalling 
pathways. To this purpose, we used the reversible tyrosine kinase, EGFR-inhibitors based on quinazolines, 
N-(3-bromophenyl)-6,7-dimethoxyquinazoline-4-amine (PD153035, IC50 of <30 pM vs. EGFR) thereafter 
named 3-B, and N-(4-bromophenyl)-6,7-dimethoxyquinazoline-4-amine, thereafter named 4-B. In this 
set of experiments, MTT assays were performed to monitor the viability of cells (i) exposed to BC-11 
reacted with preparations of 100 or 500 ng or 1 μg of isolated ATF before administering to cell 
cultures; and (ii) co-treated with BC-11 and either or both of EGFR inhibitors to check the occurrence 
of a synergistic, antagonistic or additive effect of the compounds. 
As shown in Figure 3A, pre-treatment of BC-11 with 100 ng ATF resulted in the reversion of  
BC-11 cytotoxicity, confirming its competitive effect towards drug binding to the uPa “growth-promoting” 
domain. Concerning the two EGFR inhibitors, in a pilot set of assays we first evaluated their individual 
effect towards MDA-MB231 cells after 72 h of exposure and demonstrated a dose-dependent 
impairment of cell viability with an ED50 = 35 μM for 3-B and an ED50 = 130 μM for 4-B (not shown). 
The table in Figure 2B reports the Combination Index (CI) of two-drug and three-drug co-treatments at 
constant ratios based on their ED50 values (3-B:4-B:BC-11 = 1:4:4). The data obtained point to opposing, 
strongly, antagonistic or synergistic effects of compounds 4-B and 3-B, respectively, when administered 
for 72 h to MDA-MB231 cells in association with BC-11 at a ratio based on similar efficacies. 
Interestingly, the synergistic effect of 3-B was maintained and even potentiated also in  
three-drug co-treatments. 
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Figure 3. Effect of ATF, 3-B and 4-B on BC-11 cytotoxic activity. (A) MTT assay of 
MDA-MB231 cells treated with 117 μM BC-11 (A), untreated (B) and treated with 117 μM 
BC-11 pre-adsorbed with 100 ng ATF for 72 h. Error bars correspond to s.e.m. of  
three independent measurements; (B) CI values of BC-11 in two-drug and three-drug 
associations with the EGFR inhibitors 3-B and 4-B at different effect dose levels. 
In order to obtain a more complete characterization of BC-11’s biological activity on triple-negative 
breast cancer cells, a last set of experiments was performed by incubating MDA-MB231 cells with  
a higher concentration of the drug corresponding to its ED75 at 72 h (i.e., 250 μM), and checking 
whether the enhanced cytotoxic effect could be due to the onset of additional death-inducing events 
(i.e., apoptosis, MMP collapse, ROS hyperproduction), or only to a more pronounced uPa blocking 
effect following the increase in BC-11 concentration. As expected, cell cycle analysis of the exposed 
cell preparation (Figure 4A) showed a decrease of G0/G1 phase fraction (9.69% vs. 24.63%), although 
an effect on S phase fraction was not recorded in this case. 
3-B is a known potent inhibitor of EGFR autophosphorylation that competes with the ATP binding 
site [19] and, although MDA-MB231 cells have been proven to be weakly sensitive to its effect if 
compared to other cancer cell lines [20], under the experimental conditions tested a greater than 
expected additive effect was observed. Noteworthy, exposure to 3-B was shown to suppress endogenous 
uPa secretion by MDA-MB231 cells [21] which display a markedly up-regulated expression of  
this gene [22]. 
 
Figure 4. Cont. 
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Figure 4. Effect of exposure of MDA-MB231 cells to BC-11 at its ED75 at 72 h on cell 
cycle, mitochondrial activity and apoptosis promotion. (A) DNA profiles of MDA-MB231 
cells after 72 h of culture in control conditions (lighter in the background) and in the 
presence of 250 μM BC-11 (darker superimposed). Total cell distribution is reported in the 
annexed table; (B) Panel of flow cytometric assays of control cells and parallel cultures 
exposed to 250 μM BC-11. Analysis of MMP through JC-1 staining is reported in the top 
dot plots where the percentages indicated in the bottom quadrants in each frame refer to 
low red-emitting cells that underwent dissipation of MMP. The middle dot plots report the 
result of the staining with two-colour ROS detection reagents. The percentage indicated in 
the quadrants in each frame refers to superoxide only overproducing cells (top left quadrant), 
total ROS overproducing cells (bottom right quadrant), and total ROS/superoxide 
overproducing cells (top right quadrant). Analysis of phosphatydilserine externalization 
through annexin V-FITC coupled to propidium iodide (PI) staining is reported in the 
bottom dot plots. The percentage indicated in the quadrants in each frame refers to necrotic 
annexin−/PI+ and annexin+/PI+ cells (both top quadrants) and apoptotic annexin+/PI− cells 
(bottom right quadrant). 
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Consequently, the synergistic effect might be ascribed to the drastic reduction of the amount of 
secreted uPa allowing BC-11 to block more efficiently the less concentrated binding sites of the 
enzyme released in the extracellular medium. No attempt was made to get more into mechanistic 
details of the opposite effects exerted by EGFR inhibitors 3-B and 4-B, which will be the object of  
future investigation. 
In addition, treatment with 250 µM of BC-11 was linked to an augmented subG0 fraction (64.64% 
vs. 37.63%), consistent with an increased accumulation of damaged and fragmented cells due to 
compound toxicity. Differently from the results obtained with BC-11 administered at an ED50 dose, the 
increase up to 250 μM of the drug resulted in the additional impairment of mitochondrial activity.  
As shown in the top and middle dot plots of Figure 4B, BC-11 induces the doubling of the number of 
mitochondria displaying dissipation of MMP paralleled by enhanced production of ROS (11.32% vs. 
2.71%) including the superoxide anion (5.31% vs. 0.33%). It is well-known that mitochondria are the 
major intracellular sources of ROS and that in these organelles also ROS detoxifying systems are 
actively operating in physiological conditions [23]. BC-11, therefore, is likely to induce an oxidative 
stress due to mitochondrial defence failure [24], such as structural impairment and/or loss of anti-oxidant 
matrix solutes (e.g., glutathione) through the permeability transition pores, leading to imbalance of 
ROS production, removal and extra-mitochondrial release and resulting in the increase of their net 
intracellular accumulation. Excess ROS-mediated mitochondrial permeabilization is also known to 
release factors triggering the intrinsic apoptotic cascade (e.g., [25]). This can be correlated with the 
results shown in the bottom dot plots of Figure 4B, which indicate that an increase from 2.52% up  
to 11.84% of cells showing annexin+/propidium iodide (PI)− pattern, i.e., in early apoptosis, can be 
observed after exposure to the higher concentration of BC-11. 
3. Experimental Section 
3.1. Cell Culture and Drugs 
MDA-MB231 breast tumor cells (obtained from ATCC, Manassas, VA, USA) were maintained in 
RPMI 1640 medium plus 10% foetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin, and  
2.5 mg/L amphotericin B (Invitrogen, Carlsbad, CA, USA), at 37 °C in a 5% CO2 atmosphere. The 
cells were detached from flasks with 0.05% trypsin-EDTA, counted, and plated at the necessary density 
for treatment after achieving 60%–80% confluency. 
Carbamimidothioic acid (4-boronophenyl)methyl ester hydrobromide (BC-11) was synthesized 
according to a known route or purchased from Tocris Biosciences (Bristol, UK) [26]. 
(Benzylsulfanyl)methanimidamide hydrobromide (1) was made using a literature route. Doxorubicin 
was purchased from Tocris Biosciences. Reversible tyrosine kinase, EGFR-inhibitors based on 
quinazolines, namely N-(3-bromophenyl)-6,7-dimethoxyquinazoline-4-amine and N-(4-bromophenyl)-
6,7-dimethoxyquinazoline-4-amine, were made according to literature routes as tool compounds and as 
positive assay controls [27–29]. 
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3.2. MTT Assay 
Assessment of cell viability was determined by an MTT assay [30]. Briefly, MDA-MB231 cells in 
exponential growth were plated at a concentration of 5500 cells/well in a 96-well plate, allowed to 
adhere overnight, and then treated with: (i) different concentrations of BC-11 for 24, 48 and 72 h;  
(ii) different concentrations of 1 and doxorubicin for 72 h; (iii) 117 μM BC-11 pre-adsorbed overnight 
in the cold with 100 ng of uPa-ATF [31] for 72 h; or (iv) BC-11 in association with either or both 3-B 
and 4-B compounds for 72 h at different concentrations. After addition of MTT (final concentration 
0.75 mg/mL) and incubation with the SDS-containing solubilization buffer, the absorbance of the 
dissolved formazan was measured in an automated microplate reader at 550 nm. Cell viability ratio 
was determined as the ratio between treated cells and controls and ED50/ED75 were calculated with 
Prism 5.0 software (GraphPad, La Jolla, CA, USA). The synergistic, additive or antagonistic interactions 
of co-treatment with BC-11 and EGFR inhibitors was evaluated calculating the Combination Index 
(CI) with CompuSyn software (ComboSyn Inc., Paramus, NJ, USA; [32]) taking into account that  
CIs < 1 indicate synergism, whereas CIs ≥ 1 indicate additive effect or antagonism, respectively. 
3.3. Flow Cytometry 
Flow cytometric assays were performed according to Librizzi et al. [30]. The occurrence of early 
apoptosis was evaluated using the Annexin V-FITC kit (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany) according to manufacturer’s instructions. Data were represented as dot plots using Flowing 
Software v.1.6.0., which discriminate normal cells (bottom left quadrant) from cells in early apoptosis 
(bottom right quadrant), cells in late apoptosis or early necrosis (top right quadrant), or cells undergoing 
necrosis (top left quadrant). 
The production of ROS, such as hydrogen peroxide, peroxynitrite, hydroxyl radicals, nitric oxide, 
and peroxy radical, and of superoxide was evaluated using the Total ROS/Superoxide Detection  
Kit (Enzo Life Sciences, Lausen, Switzerland) according to manufacturer’s instructions. Positive 
(pyocyanin-treated) and negative (N-acetyl-L-cysteine-treated) controls were included in the analysis, 
and data were represented as dot plots using Flowing Software v.1.6.0., which discriminate cells with 
increased total ROS production (top left quadrant), increased superoxide production (bottom right 
quadrant) and increased total ROS and superoxide production (top right quadrant). 
MMP was checked using the fluorescent dye JC1 (Molecular Probes, Eugene, OR, USA) that is 
selectively taken up into mitochondria, undergoing to a fluorescence emission shift from green (~529 nm) 
to red (~590 nm) in case of intact MMP, whereas in case of mitochondrial depolarization a decrease in 
the red/green fluorescence intensity ratio can be observed. Data were represented as dot plots using 
Flowing Software v.1.6.0., which discriminate in the bottom quadrants the amount of cells that 
undergo to loss of MMP. Cell cycle distribution was checked by PI stain after pre-incubation with Triton 
X-100 and RNase A, and analyzed with Flowing Software v.1.6.0. software. All the preparations 
assayed contained both attached and floating cells, and all the analyses were performed in a 
FACSCanto apparatus (BD Biosciences, Franklin Lakes, NJ, USA). 
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4. Conclusions 
The collective results on BC-11’s cytotoxic effect obtained in “in vitro” assays on TNBC MDA-MB231 
cells represent promising preliminary data indicating that BC-11 treatment possesses the potential for 
the development of this chemical class as an agent for the prevention and/or therapy of “aggressive” 
breast carcinoma, thus prompting further and more detailed investigations to evaluate BC-11 as  
anti-cancer compound in vivo (for reviews on bioactive boronic acids see [33,34]). 
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